These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11329095)

  • 1. The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group.
    Sharma S; Deitchman D; Eni JS; Gelperin K; Ilgenfritz JP; Blumenthal M
    Am J Ther; 1999 Jul; 6(4):181-9. PubMed ID: 11329095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute hemodynamic effects and preload-dependent cardiovascular profile of the partial phosphodiesterase inhibitor nanterinone in patients with mild to moderate heart failure.
    Remme WJ; van der Ent M; Bartels GL; van Schelven D; van Hoogenhuyze DC; Krauss XH; Kruijssen HA; Storm CJ
    Cardiovasc Drugs Ther; 1996 May; 10(2):137-44. PubMed ID: 8842505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group.
    Erhardt L; MacLean A; Ilgenfritz J; Gelperin K; Blumenthal M
    Eur Heart J; 1995 Dec; 16(12):1892-9. PubMed ID: 8682023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fosinopril. A review of its pharmacology and clinical efficacy in the management of heart failure.
    Davis R; Coukell A; McTavish D
    Drugs; 1997 Jul; 54(1):103-16. PubMed ID: 9211084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial differences in the renal response to blood pressure lowering during chronic angiotensin-converting enzyme inhibition: a prospective double-blind randomized comparison of fosinopril and lisinopril in older hypertensive patients with chronic renal insufficiency.
    Mitchell HC; Smith RD; Cutler RE; Sica D; Videen J; Thompsen-Bell S; Jones K; Bradley-Guidry C; Toto RD
    Am J Kidney Dis; 1997 Jun; 29(6):897-906. PubMed ID: 9186076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. Fosinopril Heart Failure Study Group.
    Brown EJ; Chew PH; MacLean A; Gelperin K; Ilgenfritz JP; Blumenthal M
    Am J Cardiol; 1995 Mar; 75(8):596-600. PubMed ID: 7887385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of peripheral microvascular dysfunction during long-term treatment with the angiotensin-converting enzyme inhibitor fosinopril in congestive heart failure.
    Galatius S; Wroblewski H; Sørensen V; Haunsø S; Nørgaard T; Kastrup J
    J Card Fail; 1999 Mar; 5(1):17-24. PubMed ID: 10194656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure.
    Mitrovic V; Willenbrock R; Miric M; Seferovic P; Spinar J; Dabrowski M; Kiowski W; Marks DS; Alegria E; Dukát A; Lenz K; Arens HA
    Am Heart J; 2003 Mar; 145(3):E14. PubMed ID: 12660683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of omapatrilat on hemodynamics and safety in patients with heart failure.
    Klapholz M; Thomas I; Eng C; Iteld BJ; Ponce GA; Niederman AL; Bilsker M; Heywood JT; Synhorst D
    Am J Cardiol; 2001 Sep; 88(6):657-61. PubMed ID: 11564390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group.
    Crozier I; Ikram H; Awan N; Cleland J; Stephen N; Dickstein K; Frey M; Young J; Klinger G; Makris L
    Circulation; 1995 Feb; 91(3):691-7. PubMed ID: 7828295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.
    Baruch L; Anand I; Cohen IS; Ziesche S; Judd D; Cohn JN
    Circulation; 1999 May; 99(20):2658-64. PubMed ID: 10338459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fosinopril reduces left ventricular mass in untreated hypertensive patients: a controlled trial.
    Cheung BM; Lau CP
    Br J Clin Pharmacol; 1999 Feb; 47(2):179-87. PubMed ID: 10190653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure.
    Havranek EP; Thomas I; Smith WB; Ponce GA; Bilsker M; Munger MA; Wolf RA
    J Am Coll Cardiol; 1999 Apr; 33(5):1174-81. PubMed ID: 10193713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of fosinopril on exercise tolerance, symptoms, and clinical outcomes in patients with decompensated heart failure.
    Shettigar U; Hare T; Gelperin K; Ilgenfritz JP; Deitchman D; Blumenthal M
    Congest Heart Fail; 1999; 5(1):27-34. PubMed ID: 12189330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short- and long-term effects of early fosinopril administration in patients with acute anterior myocardial infarction undergoing intravenous thrombolysis: results from the Fosinopril in Acute Myocardial Infarction Study. FAMIS Working Party.
    Borghi C; Marino P; Zardini P; Magnani B; Collatina S; Ambrosioni E
    Am Heart J; 1998 Aug; 136(2):213-25. PubMed ID: 9704681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of atenolol as add-on therapy to fosinopril in heart failure.
    Pacher R; Hülsmann M; Berger R; Koller-Strametz J; Kos T; Frey B; Dukat A; Stanek B
    Wien Klin Wochenschr; 1997 Apr; 109(7):232-8. PubMed ID: 9141231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemodynamic and hormonal effects of quinaprilat in patients with congestive heart failure.
    Mitrovic V; Mudra H; Bonzel T; Schmidt W; Strand JC; Bakovic-Alt R; Posvar EL
    Clin Pharmacol Ther; 1996 Jun; 59(6):686-98. PubMed ID: 8681494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis.
    Weinberg EO; Schoen FJ; George D; Kagaya Y; Douglas PS; Litwin SE; Schunkert H; Benedict CR; Lorell BH
    Circulation; 1994 Sep; 90(3):1410-22. PubMed ID: 8087951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the first dose response of fosinopril and captopril in congestive heart failure: a randomized, double-blind, placebo controlled study.
    Eryonucu B; Koldas L; Ayan F; Keser N; Sirmaci A
    Jpn Heart J; 2001 Mar; 42(2):185-91. PubMed ID: 11384079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.
    Murdoch DR; McDonagh TA; Farmer R; Morton JJ; McMurray JJ; Dargie HJ
    Am Heart J; 2001 May; 141(5):800-7. PubMed ID: 11320369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.